Welcome to the annual meeting for Gyre Therapeutics, Inc. Our host for today's call is Ying Luo, Chief Executive Officer of Gyre and Chair of today's meeting. I will now turn the call over to your host.
Hello and welcome to Gyre Therapeutics 2026 Annual Meeting of Shareholders. My name is Ying Luo, Gyre's Chief Executive Officer, a member of the Board of Directors, and the Chair of today's meeting. Thank you all for joining us today. Let me begin by introducing the other members of our Board of Directors. Ping Zhang, Chairman of our board. Dr. Gordon Carmichael, Dr. David Epstein, Dr. Renate Parry, Rodney Nussbaum, and Dr. Dan Weng. I would also like to introduce the other members of the management team who are joining us today. Thomas Eastling, Chief Financial Officer, Josh Bergmann, General Counsel and the Corporate Secretary, and Dr. Yue Xiong, Chief Scientific Officer. Additionally, representatives of our independent registered public accounting firm, Grant Thornton Zhitong, and our outside legal counsel, Gibson, Dunn & Crutcher, are also joining us today. Mr. Bergmann will serve as Secretary of the meeting.
A representative of the Carideo Group has been appointed Inspector of Election to examine and count proxies and votes for this meeting. This meeting will be conducted in accordance with the agenda and the rules of conduct provided on the virtual meeting website. To ensure an informative, orderly, and constructive meeting, we ask that participants adhere to these rules. First, we will address the business items before the stockholders as outlined in the proxy statement. Following the discussion and the vote on these items, we will conclude the business portion of the meeting. You may vote your shares online at any time during this meeting before the closing of the polls. The polls opened at the start of the meeting and will close immediately after the presentation and discussion of today's proposals.
The company's agents have certified that the proxy materials were made available to stockholders of record beginning on April 27th. I have received an oath signed by the Inspector of Election stating that they will faithfully execute their duties with strict impartiality. The record date was April 16th, and as of that date, 96.9 million shares of common stock were outstanding. A quorum is present, and I hereby declare the meeting properly constituted and convened. The following proposals are up for vote today. Proposal one, election of Class II directors, Dr. David Epstein and Dr. Dan Weng. Proposal two, advisory vote on executive compensation. Proposal three, ratification of Grant Thornton Zhitong as independent auditor. Proposal four, approval of the issuance of shares of common stock upon conversion of the company's Series B convertible preferred stock. The board recommends a vote for all the proposals.
We will now see if there are any questions or comments regarding these proposals.
I see no questions on the proposals.
We will close the polls shortly. If you have previously voted, it is not necessary to vote again unless you wish to change your vote or you requested a legal proxy. Any stockholder who hasn't yet voted or wishes to change their vote should do so now by clicking on the voting button on the web portal and following the instructions. Since everyone has had the opportunity to vote, I now declare the polls are closed. According to the preliminary results, we have received votes and proxies sufficient to elect each of the director nominees and approve the other proposals voted on today. The final vote totals, including votes validly received at this meeting, will be tabulated and filed with the SEC. This concludes the business portion of our annual meeting. Thank you again for your time, your trust, and your continued support.
We are excited about the road ahead and look forward to keeping you updated on our progress. This meeting is now adjourned.
This now concludes the meeting. Thank you for joining, and have a pleasant day.